{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/empowering-biotech-innovations-end-end-solutions-your-immunotherapy-trials#webpage",
"url": "https://www.fortrea.com/insights/empowering-biotech-innovations-end-end-solutions-your-immunotherapy-trials",
"name": "Empowering biotech innovations: End-to-end solutions for your immunotherapy trials",
"description": "This Fortrea case study highlights how a U.S.-based biotech developing a novel intratumoral immunotherapy treatment partnered with Fortrea to support its transition from largely in-house development activities to a more comprehensive clinical development strategy. As the sponsor expanded its oncology pipeline and prepared for a Phase I study, it required a partner capable of providing scientific, operational, and strategic guidance across multiple aspects of development. Fortrea conducted a holistic evaluation of the proposed protocol, assessed the patient and provider experience associated with the treatment approach, generated data-driven patient enrollment projections, proposed a train-the-trainer model for study procedures, and identified protocol modifications to better align with regulatory requirements. By combining clinical development expertise, operational planning, site insights, and strategic consultation, Fortrea helped the sponsor refine its clinical approach, anticipate potential study challenges, strengthen development planning, and establish a foundation for continuity from early development through future commercialization objectives."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Empowering biotech innovations: End-to-end solutions for your immunotherapy trials",
"item": "https://www.fortrea.com/insights/empowering-biotech-innovations-end-end-solutions-your-immunotherapy-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/empowering-biotech-innovations-end-end-solutions-your-immunotherapy-trials#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/empowering-biotech-innovations-end-end-solutions-your-immunotherapy-trials#webpage"
},
"headline": "Immunotherapy Clinical Development: Optimizing Protocol Design, Enrollment Strategy and Trial Planning for Emerging Biotechs | Fortrea Case Study",
"description": "This Fortrea case study highlights how a U.S.-based biotech developing a novel intratumoral immunotherapy treatment partnered with Fortrea to support its transition from largely in-house development activities to a more comprehensive clinical development strategy. As the sponsor expanded its oncology pipeline and prepared for a Phase I study, it required a partner capable of providing scientific, operational, and strategic guidance across multiple aspects of development. Fortrea conducted a holistic evaluation of the proposed protocol, assessed the patient and provider experience associated with the treatment approach, generated data-driven patient enrollment projections, proposed a train-the-trainer model for study procedures, and identified protocol modifications to better align with regulatory requirements. By combining clinical development expertise, operational planning, site insights, and strategic consultation, Fortrea helped the sponsor refine its clinical approach, anticipate potential study challenges, strengthen development planning, and establish a foundation for continuity from early development through future commercialization objectives.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/biotech-innovations-immunotherapy-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}